Cell Therapy for Craniofacial Bone Defects

Trial Profile

Cell Therapy for Craniofacial Bone Defects

Phase of Trial: Phase I/II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Ixmyelocel-T (Primary)
  • Indications Alveolar bone loss
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 May 2015 Planned End Date changed from 1 Dec 2014 to 1 Apr 2016, according to ClinicalTrials.gov record.
    • 19 May 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top